Extended Partnership with NecstGen

Extended Partnership with NecstGen

Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
4.25 Million in Seed Extension Round

4.25 Million in Seed Extension Round

Rotterdam, July 11 2024 Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round. This round includes a new investor InnovationQuarter and...
Pan Cancer T are EIT Health Catapult Finalists

Pan Cancer T are EIT Health Catapult Finalists

On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich. This marks the culmination of the EIT Health Catapult program, a unique competition and training programme that...